Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fusion-VAC-XS15 and Atezolizumab in Fibrolamellar Hepatocellular Carcinoma
NCT05937295Phase 1Recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DNAJB1-PRKACA peptide vaccine in fibrolamellar hepatocellular carcinoma (FLHCC), sponsored by University Hospital Tübingen. Primary endpoints: Induction of peptide specific T-cell responses at 1 year and Incidence of Treatment-Emergent Adverse Events at 1 year. Started Sep 2023; status: recruiting.
02
Drugs
DNAJB1-PRKACA peptide vaccine
03
Conditions
fibrolamellar hepatocellular carcinoma (FLHCC)
Beyond the preview
Go deeper on NCT05937295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937295.